Schneider Downs Wealth Management Advisors LP Has $777,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Schneider Downs Wealth Management Advisors LP lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,809 shares of the company’s stock after purchasing an additional 475 shares during the period. Schneider Downs Wealth Management Advisors LP’s holdings in Johnson & Johnson were worth $777,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. OLD Mission Capital LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $362,000. Ironwood Wealth Management LLC. raised its holdings in Johnson & Johnson by 37.3% in the 1st quarter. Ironwood Wealth Management LLC. now owns 10,161 shares of the company’s stock valued at $1,670,000 after acquiring an additional 2,761 shares during the period. Hoylecohen LLC boosted its holdings in shares of Johnson & Johnson by 31.3% during the first quarter. Hoylecohen LLC now owns 126,382 shares of the company’s stock worth $20,771,000 after acquiring an additional 30,109 shares during the period. MBL Wealth LLC boosted its stake in Johnson & Johnson by 23.9% in the 1st quarter. MBL Wealth LLC now owns 5,929 shares of the company’s stock valued at $974,000 after purchasing an additional 1,144 shares during the period. Finally, Fragasso Group Inc. boosted its position in shares of Johnson & Johnson by 0.9% in the first quarter. Fragasso Group Inc. now owns 12,893 shares of the company’s stock valued at $2,119,000 after acquiring an additional 120 shares during the period. Institutional investors and hedge funds own 67.14% of the company’s stock.

NYSE:JNJ opened at $160.24 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.11 and a current ratio of 1.34. Johnson & Johnson has a fifty-two week low of $142.86 and a fifty-two week high of $179.92. The company has a 50 day simple moving average of $162.64 and a two-hundred day simple moving average of $167.35. The company has a market capitalization of $421.85 billion, a PE ratio of 23.95, a P/E/G ratio of 2.38 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Monday, October 18th. The company reported $2.60 EPS for the quarter, beating the Zacks’ consensus estimate of $2.35 by $0.25. The company had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. The company’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.20 EPS. Research analysts predict that Johnson & Johnson will post 9.78 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 7th. Shareholders of record on Tuesday, November 23rd will be paid a dividend of $1.06 per share. The ex-dividend date of this dividend is Monday, November 22nd. This represents a $4.24 dividend on an annualized basis and a yield of 2.65%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 63.38%.

A number of analysts have issued reports on JNJ shares. Wells Fargo & Company reissued a “buy” rating on shares of Johnson & Johnson in a report on Thursday, October 7th. Morgan Stanley lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a research note on Tuesday, September 7th. Raymond James reduced their target price on Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, October 20th. SVB Leerink reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price objective on the stock in a research note on Friday, October 22nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $187.78.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Story: Closed-End Mutual Funds (CEFs)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.